{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T14:16:12Z","timestamp":1772720172756,"version":"3.50.1"},"reference-count":270,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T00:00:00Z","timestamp":1636070400000},"content-version":"am","delay-in-days":308,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.critrevonc.2020.103127","type":"journal-article","created":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T22:39:40Z","timestamp":1603233580000},"page":"103127","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Multikinase inhibitor-induced liver injury in patients with cancer: A review for clinicians"],"prefix":"10.1016","volume":"157","author":[{"given":"Camille","family":"Houron","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Danielou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Mir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Fromenty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Perlemuter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cosmin Sebastian","family":"Voican","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.critrevonc.2020.103127_bib0005","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/10245330600937929","article-title":"Imatinib-induced immune hepatitis: case report and literature review","volume":"12","author":"Al Sobhi","year":"2007","journal-title":"Hematology"},{"issue":"6","key":"10.1016\/j.critrevonc.2020.103127_bib0010","doi-asserted-by":"crossref","DOI":"10.1097\/COC.0b013e31802b4ef7","article-title":"An acute hepatitis resembling autoimmune hepatitis occurring during imatinib therapy in a gastrointestinal stromal tumor patient","volume":"32","author":"Aliberti","year":"2009","journal-title":"Am. J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2020.103127_bib0015","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1080\/14737140.2016.1192469","article-title":"The safety and efficacy of cobimetinib for the treatment of BRAF V600E or V600K melanoma","volume":"16","author":"Amaral","year":"2016","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2020.103127_bib0020","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/liv.14271","article-title":"Diagnostic and prognostic assessment of suspected drug-induced liver injury in clinical practice","volume":"40","author":"Andrade","year":"2020","journal-title":"Liver Int."},{"issue":"6","key":"10.1016\/j.critrevonc.2020.103127_bib0025","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/S1470-2045(14)70138-X","article-title":"Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"15","author":"Andre","year":"2014","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2020.103127_bib0030","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s12094-016-1498-9","article-title":"Safety of vemurafenib in patients with BRAF (V600) mutated metastatic melanoma: the Spanish experience","volume":"18","author":"Arance","year":"2016","journal-title":"Clin. Transl. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2020.103127_bib0035","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S1470-2045(15)00515-X","article-title":"Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial","volume":"17","author":"Armstrong","year":"2016","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2020.103127_bib0040","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0973-6883(11)60112-6","article-title":"Erlotinib-induced hepatotoxicity-clinical presentation and successful management: a case report","volume":"1","author":"Arora","year":"2011","journal-title":"J. Clin. Exp. Hepatol."},{"issue":"9","key":"10.1016\/j.critrevonc.2020.103127_bib0045","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","article-title":"Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial","volume":"17","author":"Ascierto","year":"2016","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2020.103127_bib0050","article-title":"Imatinib (Gleevec)-induced hepatotoxicity","volume":"39","author":"Ayoub","year":"2005","journal-title":"J. Clin. Gastroenterol."},{"issue":"36","key":"10.1016\/j.critrevonc.2020.103127_bib0055","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.1200\/JCO.2013.50.9448","article-title":"Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial","volume":"31","author":"Azim","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2020.103127_bib0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.dld.2013.01.002","article-title":"A phase II study of sunitinib in advanced hepatocellular carcinoma","volume":"45","author":"Barone","year":"2013","journal-title":"Dig. Liver Dis."},{"issue":"4","key":"10.1016\/j.critrevonc.2020.103127_bib0065","doi-asserted-by":"crossref","DOI":"10.1007\/s10637-011-9722-5","article-title":"A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer","volume":"30","author":"Beardsley","year":"2012","journal-title":"Invest. New Drugs"},{"issue":"2","key":"10.1016\/j.critrevonc.2020.103127_bib0070","doi-asserted-by":"crossref","DOI":"10.1159\/000479732","article-title":"Fatal acute liver failure as a consequence of regorafenib treatment in a metastatic Colon Cancer","volume":"10","author":"Bechade","year":"2017","journal-title":"Case Rep. Oncol."},{"issue":"290","key":"10.1016\/j.critrevonc.2020.103127_bib0075","article-title":"Randomized phase II study of pemetrexed\/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer","volume":"14","author":"Belani","year":"2014","journal-title":"BMC Cancer"},{"issue":"11","key":"10.1016\/j.critrevonc.2020.103127_bib0080","doi-asserted-by":"crossref","DOI":"10.1016\/0895-4356(93)90102-7","article-title":"Causality assessment of adverse reactions to drugs--II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge","volume":"46","author":"Benichou","year":"1993","journal-title":"J. Clin. Epidemiol."},{"issue":"4","key":"10.1016\/j.critrevonc.2020.103127_bib0085","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.3390\/cancers6042035","article-title":"Gefitinib plus interleukin-2 in advanced non-small cell lung cancer patients previously treated with chemotherapy","volume":"6","author":"Bersanelli","year":"2014","journal-title":"Cancers (Basel)."},{"issue":"10","key":"10.1016\/j.critrevonc.2020.103127_bib0090","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/S1470-2045(10)70203-5","article-title":"Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study","volume":"11","author":"Bible","year":"2010","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2020.103127_bib0095","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1053\/j.gastro.2013.02.006","article-title":"Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland","volume":"144","author":"Bjornsson","year":"2013","journal-title":"Gastroenterology."},{"key":"10.1016\/j.critrevonc.2020.103127_bib0100","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ejca.2017.04.007","article-title":"Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF(V600) mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders\u2019 analysis","volume":"79","author":"Blank","year":"2017","journal-title":"Eur. J. Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2020.103127_bib0105","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S1470-2045(15)70105-1","article-title":"Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial","volume":"16","author":"Blay","year":"2015","journal-title":"Lancet Oncol."},{"issue":"339","key":"10.1016\/j.critrevonc.2020.103127_bib0110","article-title":"Phase II study of axitinib with doublet chemotherapy in patients with advanced squamous non-small-cell lung cancer","volume":"15","author":"Bondarenko","year":"2015","journal-title":"BMC Cancer"},{"issue":"8","key":"10.1016\/j.critrevonc.2020.103127_bib0115","doi-asserted-by":"crossref","DOI":"10.1080\/10428190802136384","article-title":"Dasatinib-induced acute hepatitis","volume":"49","author":"Bonvin","year":"2008","journal-title":"Leuk. Lymphoma"},{"issue":"13","key":"10.1016\/j.critrevonc.2020.103127_bib0120","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S1470-2045(15)00198-9","article-title":"Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"16","author":"Bruix","year":"2015","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2020.103127_bib0125","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.cld.2016.08.009","article-title":"Drug hepatotoxicity: newer agents","volume":"21","author":"Bunchorntavakul","year":"2017","journal-title":"Clin. Liver Dis. (Hoboken)"},{"issue":"16","key":"10.1016\/j.critrevonc.2020.103127_bib0130","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1182\/blood-2014-10-606038","article-title":"Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib","volume":"125","author":"Byrd","year":"2015","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.critrevonc.2020.103127_bib0135","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1093\/annonc\/mdr261","article-title":"Phase II study of single-agent bosutinib, a Src\/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy","volume":"23","author":"Campone","year":"2012","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2020.103127_bib0140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0114008","article-title":"Efficacy and safety of crizotinib among Chinese EML4-ALK-positive, advanced-stage non-small cell lung cancer patients","volume":"9","author":"Cao","year":"2014","journal-title":"PLoS One"},{"issue":"35","key":"10.1016\/j.critrevonc.2020.103127_bib0145","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2006.07.8261","article-title":"Liver toxicity after treatment with gefitinib and anastrozole: drug-drug interactions through cytochrome p450?","volume":"24","author":"Carlini","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2020.103127_bib0150","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s10549-012-1997-5","article-title":"A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer","volume":"133","author":"Carlson","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"issue":"7","key":"10.1016\/j.critrevonc.2020.103127_bib0155","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/ajg.2014.131","article-title":"ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury","volume":"109","author":"Chalasani","year":"2014","journal-title":"Am. J. Gastroenterol."},{"issue":"10-11","key":"10.1016\/j.critrevonc.2020.103127_bib0160","article-title":"[Glivec induced autoimmune hepatitis]","volume":"33","author":"Charier","year":"2009","journal-title":"Gastroenterol. Clin. Biol."},{"issue":"3","key":"10.1016\/j.critrevonc.2020.103127_bib0165","doi-asserted-by":"crossref","first-page":"878","DOI":"10.3892\/ol.2013.1756","article-title":"Rechallenge with gefitinib following severe drug-induced hepatotoxicity in a patient with advanced non-small cell lung cancer: a case report and literature review","volume":"7","author":"Chen","year":"2014","journal-title":"Oncol. Lett."},{"issue":"1","key":"10.1016\/j.critrevonc.2020.103127_bib0170","article-title":"Mitochondrial pathway-mediated apoptosis is associated with erlotinib-induced cytotoxicity in hepatic cells","volume":"15","author":"Chen","year":"2018","journal-title":"Oncol. Lett."},{"issue":"32","key":"10.1016\/j.critrevonc.2020.103127_bib0175","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.1200\/JCO.2012.45.8372","article-title":"Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial","volume":"31","author":"Cheng","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2020.103127_bib0180","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/hep.28600","article-title":"Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma","volume":"64","author":"Cheng","year":"2016","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.critrevonc.2020.103127_bib0185","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1007\/s10637-011-9763-9","article-title":"Nilotinib in patients with metastatic melanoma harboring KIT gene aberration","volume":"30","author":"Cho","year":"2012","journal-title":"Invest. New Drugs"},{"issue":"2","key":"10.1016\/j.critrevonc.2020.103127_bib0190","doi-asserted-by":"crossref","DOI":"10.1002\/jcph.1010","article-title":"Effects of concomitant medication use on gefitinib-induced hepatotoxicity","volume":"58","author":"Cho","year":"2018","journal-title":"J. Clin. Pharmacol."},{"issue":"19","key":"10.1016\/j.critrevonc.2020.103127_bib0195","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","article-title":"Cabozantinib versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Choueiri","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.critrevonc.2020.103127_bib0200","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S1470-2045(16)30107-3","article-title":"Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial","volume":"17","author":"Choueiri","year":"2016","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2020.103127_bib0205","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0090909","article-title":"Multicenter phase II study of sequential radioembolization-sorafenib therapy for inoperable hepatocellular carcinoma","volume":"9","author":"Chow","year":"2014","journal-title":"PLoS One"},{"issue":"19","key":"10.1016\/j.critrevonc.2020.103127_bib0210","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2020.103127_bib0215","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s10549-012-2369-x","article-title":"A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer","volume":"137","author":"Cristofanilli","year":"2013","journal-title":"Breast Cancer Res. Treat."},{"issue":"3","key":"10.1016\/j.critrevonc.2020.103127_bib0220","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/ajh.20486","article-title":"Imatinib mesylate as a cause of acute liver failure","volume":"81","author":"Cross","year":"2006","journal-title":"Am. J. Hematol."},{"issue":"5","key":"10.1016\/j.critrevonc.2020.103127_bib0225","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1053\/j.gastro.2011.07.051","article-title":"Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury","volume":"141","author":"Davern","year":"2011","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.critrevonc.2020.103127_bib0230","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","article-title":"Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial","volume":"18","author":"Davies","year":"2017","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2020.103127_bib0235","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jhep.2018.01.033","article-title":"Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors","volume":"68","author":"De Martin","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.critrevonc.2020.103127_bib0240","doi-asserted-by":"crossref","first-page":"355","DOI":"10.4137\/CMO.S8305","article-title":"Efficacy and tolerability of pharmacotherapy options for the treatment of medullary thyroid cancer","volume":"6","author":"Deshpande","year":"2012","journal-title":"Clin. Med. Insights Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2020.103127_bib0245","article-title":"Imatinib mesylate-induced acute hepatitis with autoimmune features","volume":"18","author":"Dhalluin-Venier","year":"2006","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"issue":"4","key":"10.1016\/j.critrevonc.2020.103127_bib0250","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.jtho.2016.11.2236","article-title":"Risk of treatment-related toxicities from EGFR tyrosine kinase inhibitors: a meta-analysis of clinical trials of gefitinib, erlotinib, and afatinib in advanced EGFR-Mutated non-small cell lung Cancer","volume":"12","author":"Ding","year":"2017","journal-title":"J. Thorac. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2020.103127_bib0255","article-title":"Cardiotoxicity of anticancer therapeutics","volume":"5","author":"Dong","year":"2018","journal-title":"Front. Cardiovasc. Med."},{"issue":"10020","key":"10.1016\/j.critrevonc.2020.103127_bib0260","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(15)00667-4","article-title":"Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study","volume":"387","author":"Dreyling","year":"2016","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.critrevonc.2020.103127_bib0265","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S1470-2045(16)30562-9","article-title":"Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial","volume":"17","author":"Drilon","year":"2016","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2020.103127_bib0270","article-title":"[Treatment with erlotinib after gefitinib induced hepatotoxicity: literature review and case report]","volume":"69","author":"Durand","year":"2014","journal-title":"Therapie"},{"issue":"8","key":"10.1016\/j.critrevonc.2020.103127_bib0275","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/S1470-2045(14)70024-5","article-title":"Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial","volume":"15","author":"Dutton","year":"2014","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2020.103127_bib0280","doi-asserted-by":"crossref","DOI":"10.1038\/bjc.2013.801","article-title":"S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma","volume":"110","author":"El-Khoueiry","year":"2014","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2020.103127_bib0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygyno.2015.12.025","article-title":"Temsirolimus in women with platinum-refractory\/resistant ovarian cancer or advanced\/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8)","volume":"140","author":"Emons","year":"2016","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2020.103127_bib0290","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s00280-014-2568-8","article-title":"TACE plus sorafenib for the treatment of hepatocellular carcinoma: results of the multicenter, phase II SOCRATES trial","volume":"74","author":"Erhardt","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"2","key":"10.1016\/j.critrevonc.2020.103127_bib0295","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"Electronic address eee, European Association for the Study of the L. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","author":"European Association for the Study of the Liver","year":"2017","journal-title":"J. Hepatol."},{"issue":"6","key":"10.1016\/j.critrevonc.2020.103127_bib0300","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","article-title":"Electronic address eee, clinical practice guideline panel C, panel m, representative EGB. EASL clinical practice guidelines: drug-induced liver injury","volume":"70","author":"European Association for the Study of the Liver","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.critrevonc.2020.103127_bib0305","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1186\/1471-2407-12-590","article-title":"Fatal case of sorafenib-associated idiosyncratic hepatotoxicity in the adjuvant treatment of a patient with renal cell carcinoma","volume":"12","author":"Fairfax","year":"2012","journal-title":"BMC Cancer"},{"issue":"6 Suppl","key":"10.1016\/j.critrevonc.2020.103127_bib0310","article-title":"Corticosteroids can reverse severe imatinib-induced hepatotoxicity","volume":"91","author":"Ferrero","year":"2006","journal-title":"Haematologica."},{"issue":"1","key":"10.1016\/j.critrevonc.2020.103127_bib0315","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2165\/00002018-200932010-00005","article-title":"Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct","volume":"32","author":"Fontana","year":"2009","journal-title":"Drug Saf."},{"issue":"1","key":"10.1016\/j.critrevonc.2020.103127_bib0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygyno.2010.05.033","article-title":"A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer","volume":"119","author":"Friedlander","year":"2010","journal-title":"Gynecol. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2020.103127_bib0325","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1157\/13111687","article-title":"[Imatinib-induced toxic hepatitis: description of two cases and review of the literature]","volume":"30","author":"Fuster","year":"2007","journal-title":"Gastroenterol. Hepatol. (N Y)"},{"issue":"10","key":"10.1016\/j.critrevonc.2020.103127_bib0330","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1002\/ajh.23788","article-title":"Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia","volume":"89","author":"Gambacorti-Passerini","year":"2014","journal-title":"Am. J. Hematol."},{"issue":"7","key":"10.1016\/j.critrevonc.2020.103127_bib0335","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/ajh.23728","article-title":"Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: minimum 24-month follow-up","volume":"89","author":"Gambacorti-Passerini","year":"2014","journal-title":"Am. J. Hematol."},{"issue":"10","key":"10.1016\/j.critrevonc.2020.103127_bib0340","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1007\/s00204-020-02885-1","article-title":"Drug induced liver injury: an update","volume":"94","author":"Garcia-Cortes","year":"2020","journal-title":"Arch. Toxicol."},{"issue":"5","key":"10.1016\/j.critrevonc.2020.103127_bib0345","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdh188","article-title":"Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors","volume":"15","author":"Giaccone","year":"2004","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2020.103127_bib0350","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1586\/14737140.2014.986103","article-title":"ALK-rearranged non-small cell lung cancers: how best to optimize the safety of crizotinib in clinical practice?","volume":"15","author":"Girard","year":"2015","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"2","key":"10.1016\/j.critrevonc.2020.103127_bib0355","doi-asserted-by":"crossref","DOI":"10.14309\/crj.0000000000000011","article-title":"Histopathological features of drug-induced liver injury secondary to osimertinib","volume":"6","author":"Gonzalez","year":"2019","journal-title":"ACG Case Rep. J."},{"issue":"8","key":"10.1016\/j.critrevonc.2020.103127_bib0360","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1470-2045(09)70162-7","article-title":"Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial","volume":"10","author":"Gore","year":"2009","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2020.103127_bib0365","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/S1470-2045(16)30508-3","article-title":"Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study","volume":"17","author":"Goss","year":"2016","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2020.103127_bib0370","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.lungcan.2013.07.003","article-title":"A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC)","volume":"82","author":"Goto","year":"2013","journal-title":"Lung Cancer."},{"issue":"24","key":"10.1016\/j.critrevonc.2020.103127_bib0375","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1200\/JCO.2011.41.2056","article-title":"First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial","volume":"30","author":"Gridelli","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.critrevonc.2020.103127_bib0380","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1200\/JCO.2011.39.0823","article-title":"Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study","volume":"30","author":"Guarneri","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103127_bib0385","doi-asserted-by":"crossref","DOI":"10.1136\/bcr.11.2010.3516","article-title":"Recurrent imatinib-induced hepatotoxicity in a chronic myeloid leukaemia patient successfully managed with prednisone","volume":"2011","author":"Gupta","year":"2011","journal-title":"BMJ Case Rep."},{"issue":"29","key":"10.1016\/j.critrevonc.2020.103127_bib0390","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2008.16.3279","article-title":"Phase II trial of sorafenib in advanced thyroid cancer","volume":"26","author":"Gupta-Abramson","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2020.103127_bib0395","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.critrevonc.2020.103127_bib0400","doi-asserted-by":"crossref","DOI":"10.1007\/s12185-013-1474-x","article-title":"Treatment with dasatinib for chronic myeloid leukemia following imatinib-induced hepatotoxicity","volume":"99","author":"Harbaum","year":"2014","journal-title":"Int. J. Hematol."},{"issue":"5","key":"10.1016\/j.critrevonc.2020.103127_bib0405","doi-asserted-by":"crossref","first-page":"470","DOI":"10.2174\/138920009788897975","article-title":"Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects","volume":"10","author":"Hartmann","year":"2009","journal-title":"Curr. Drug Metab."},{"issue":"8","key":"10.1016\/j.critrevonc.2020.103127_bib0410","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1200\/JCO.2009.25.4029","article-title":"Phase I\/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer","volume":"28","author":"Haura","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"18","key":"10.1016\/j.critrevonc.2020.103127_bib0415","doi-asserted-by":"crossref","first-page":"6061","DOI":"10.1158\/1078-0432.CCR-11-1071","article-title":"Phase II trial of dasatinib in patients with metastatic breast cancer using real-time pharmacodynamic tissue biomarkers of Src inhibition to escalate dosing","volume":"17","author":"Herold","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"10089","key":"10.1016\/j.critrevonc.2020.103127_bib0420","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(17)30565-2","article-title":"Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial","volume":"390","author":"Hida","year":"2017","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.critrevonc.2020.103127_bib0425","doi-asserted-by":"crossref","DOI":"10.1007\/s10637-018-0608-7","article-title":"Successful oral desensitization with osimertinib following osimertinib-induced fever and hepatotoxicity: a case report","volume":"36","author":"Hirabayashi","year":"2018","journal-title":"Invest. New Drugs"},{"issue":"33","key":"10.1016\/j.critrevonc.2020.103127_bib0430","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2004.00.6650","article-title":"Side effects related to cancer treatment: CASE 1. Hepatitis following treatment with gefitinib","volume":"23","author":"Ho","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"14","key":"10.1016\/j.critrevonc.2020.103127_bib0435","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2014.56.2082","article-title":"Multicenter phase II trial of temsirolimus and Bevacizumab in pancreatic neuroendocrine tumors","volume":"33","author":"Hobday","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2020.103127_bib0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2015.01.003","article-title":"Efficacy and safety of acetylcysteine in \"non-acetaminophen\" acute liver failure: a meta-analysis of prospective clinical trials","volume":"39","author":"Hu","year":"2015","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"issue":"3","key":"10.1016\/j.critrevonc.2020.103127_bib0445","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2125.2009.03459.x","article-title":"Three cases of severe hepatic impairment caused by erlotinib","volume":"68","author":"Huang","year":"2009","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"7","key":"10.1016\/j.critrevonc.2020.103127_bib0450","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1470-2045(15)00051-0","article-title":"Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial","volume":"16","author":"Hurvitz","year":"2015","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2020.103127_bib0455","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1200\/JCO.2008.21.6994","article-title":"Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma","volume":"28","author":"Hutson","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2020.103127_bib0460","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/jmv.23827","article-title":"Serological cross reactivity to CMV and EBV causes problems in the diagnosis of acute hepatitis E virus infection","volume":"86","author":"Hyams","year":"2014","journal-title":"J. Med. Virol."},{"issue":"1","key":"10.1016\/j.critrevonc.2020.103127_bib0465","doi-asserted-by":"crossref","first-page":"10811","DOI":"10.1038\/s41598-017-11321-x","article-title":"Low body surface area predicts hepatotoxicity of nintedanib in patients with idiopathic pulmonary fibrosis","volume":"7","author":"Ikeda","year":"2017","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.critrevonc.2020.103127_bib0470","doi-asserted-by":"crossref","DOI":"10.1532\/IJH97.05034","article-title":"Severe hepatic injury caused by imatinib mesylate administered for the treatment of chronic myeloid leukemia and the efficacy of prednisolone for its management","volume":"82","author":"Ikuta","year":"2005","journal-title":"Int. J. Hematol."},{"issue":"5","key":"10.1016\/j.critrevonc.2020.103127_bib0475","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1093\/jjco\/hyv011","article-title":"Efficacy and safety of axitinib in combination with gemcitabine in advanced pancreatic cancer: subgroup analyses by region, including Japan, from the global randomized Phase III trial","volume":"45","author":"Ioka","year":"2015","journal-title":"Jpn. J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2020.103127_bib0480","doi-asserted-by":"crossref","DOI":"10.1038\/sj.leu.2402910","article-title":"Histological features of acute hepatitis after imatinib mesylate treatment","volume":"17","author":"James","year":"2003","journal-title":"Leukemia."},{"issue":"2","key":"10.1016\/j.critrevonc.2020.103127_bib0485","doi-asserted-by":"crossref","DOI":"10.1080\/10428194.2017.1346251","article-title":"Ibrutinib-induced acute liver failure","volume":"59","author":"Kahn","year":"2018","journal-title":"Leuk. Lymphoma"},{"issue":"1","key":"10.1016\/j.critrevonc.2020.103127_bib0490","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/neuonc\/nou148","article-title":"Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma","volume":"17","author":"Kaley","year":"2015","journal-title":"Neuro Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2020.103127_bib0495","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.jhep.2018.05.013","article-title":"Pharmacogenomics of drug-induced liver injury (DILI): molecular biology to clinical applications","volume":"69","author":"Kaliyaperumal","year":"2018","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.critrevonc.2020.103127_bib0500","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.critrevonc.2020.103127_bib0505","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1182\/blood-2013-07-513937","article-title":"Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors","volume":"123","author":"Kantarjian","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.critrevonc.2020.103127_bib0510","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.3109\/0284186X.2013.782103","article-title":"Risk of liver toxicity with the angiogenesis inhibitor pazopanib in cancer patients","volume":"52","author":"Kapadia","year":"2013","journal-title":"Acta Oncol. (Madr)"},{"issue":"5","key":"10.1016\/j.critrevonc.2020.103127_bib0515","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.eururo.2014.01.035","article-title":"Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma","volume":"66","author":"Karam","year":"2014","journal-title":"Eur. Urol."},{"issue":"3","key":"10.1016\/j.critrevonc.2020.103127_bib0520","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1093\/jjco\/hyv184","article-title":"A randomized, double-blind, placebo-controlled, Phase III study of pazopanib in patients with soft tissue sarcoma: results from the Japanese subgroup","volume":"46","author":"Kawai","year":"2016","journal-title":"Jpn. J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2020.103127_bib0525","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2165\/00003495-200969020-00006","article-title":"A review of its use in advanced hepatocellular carcinoma","volume":"69","author":"Keating","year":"2009","journal-title":"Drugs"},{"issue":"19","key":"10.1016\/j.critrevonc.2020.103127_bib0530","doi-asserted-by":"crossref","first-page":"e588","DOI":"10.1200\/JCO.2010.34.3368","article-title":"Safe and successful treatment with erlotinib after gefitinib-induced hepatotoxicity: difference in metabolism as a possible mechanism","volume":"29","author":"Kijima","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2020.103127_bib0535","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1080\/10428190412331272721","article-title":"Severe hepatitis and complete molecular response caused by imatinib mesylate: possible association of its serum concentration with clinical outcomes","volume":"45","author":"Kikuchi","year":"2004","journal-title":"Leuk. Lymphoma"},{"issue":"4","key":"10.1016\/j.critrevonc.2020.103127_bib0540","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2012.43.5966","article-title":"Phase II study of the MEK1\/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor","volume":"31","author":"Kim","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2020.103127_bib0545","article-title":"Regorafenib as salvage treatment in korean patients with refractory metastatic colorectal Cancer","volume":"47","author":"Kim","year":"2015","journal-title":"Cancer Res. Treat."},{"issue":"4","key":"10.1016\/j.critrevonc.2020.103127_bib0550","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S1470-2045(15)00614-2","article-title":"Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial","volume":"17","author":"Kim","year":"2016","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2020.103127_bib0555","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1002\/cncr.30537","article-title":"Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01)","volume":"123","author":"Kim","year":"2017","journal-title":"Cancer"},{"issue":"27","key":"10.1016\/j.critrevonc.2020.103127_bib0560","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2011.41.0332","article-title":"Severe pazopanib-induced hepatotoxicity: clinical and histologic course in two patients","volume":"30","author":"Klempner","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2020.103127_bib0565","doi-asserted-by":"crossref","DOI":"10.1007\/s00280-012-1831-0","article-title":"A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer","volume":"69","author":"Kobayashi","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"4","key":"10.1016\/j.critrevonc.2020.103127_bib0570","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1159\/000111092","article-title":"Early imatinib-mesylate-induced hepatotoxicity in chronic myelogenous leukaemia","volume":"118","author":"Kong","year":"2007","journal-title":"Acta Haematol."},{"issue":"6","key":"10.1016\/j.critrevonc.2020.103127_bib0575","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s00280-015-2730-y","article-title":"Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer","volume":"75","author":"Kordes","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"7","key":"10.1016\/j.critrevonc.2020.103127_bib0580","doi-asserted-by":"crossref","DOI":"10.1038\/bjc.2013.530","article-title":"A phase II study evaluating the toxicity and efficacy of single-agent temsirolimus in chemotherapy-naive castration-resistant prostate cancer","volume":"109","author":"Kruczek","year":"2013","journal-title":"Br. J. Cancer"},{"issue":"10126","key":"10.1016\/j.critrevonc.2020.103127_bib0585","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.critrevonc.2020.103127_bib0590","doi-asserted-by":"crossref","DOI":"10.2169\/internalmedicine.51.6285","article-title":"Successful treatment of non-small cell lung cancer with gefitinib after severe erlotinib-related hepatotoxicity","volume":"51","author":"Kunimasa","year":"2012","journal-title":"Intern. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2020.103127_bib0595","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40792-016-0131-z","article-title":"Successful treatment for sorafenib-induced liver dysfunction: a report of case with liver biopsy","volume":"2","author":"Kuroda","year":"2016","journal-title":"Surg. Case Rep."},{"issue":"1","key":"10.1016\/j.critrevonc.2020.103127_bib0600","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3892\/ol.2015.3853","article-title":"Immunosuppressant therapy successfully improved regorafenib-induced severe hepatic injury in a patient with metastatic gastrointestinal stromal tumor: a case report","volume":"11","author":"Kuwayama","year":"2016","journal-title":"Oncol. Lett."},{"issue":"18","key":"10.1016\/j.critrevonc.2020.103127_bib0605","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","article-title":"Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer","volume":"363","author":"Kwak","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2020.103127_bib0610","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/hed.23898","article-title":"Phase II trial evaluating the efficacy of sorafenib (BAY 43-9006) and correlating early fluorodeoxyglucose positron emission tomography-CT response to outcome in patients with recurrent and\/or metastatic head and neck cancer","volume":"38","author":"Lalami","year":"2016","journal-title":"Head Neck"},{"issue":"20","key":"10.1016\/j.critrevonc.2020.103127_bib0615","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.critrevonc.2020.103127_bib0620","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-16-1293","article-title":"FDA approval: alectinib for the treatment of metastatic, ALK-Positive non-small cell lung Cancer Following crizotinib","volume":"22","author":"Larkins","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2020.103127_bib0625","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1002\/hep.22177","article-title":"Acute liver failure: summary of a workshop","volume":"47","author":"Lee","year":"2008","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.critrevonc.2020.103127_bib0630","doi-asserted-by":"crossref","DOI":"10.1038\/bjc.2013.432","article-title":"A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas","volume":"109","author":"Lee","year":"2013","journal-title":"Br. J. Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2020.103127_bib0635","doi-asserted-by":"crossref","DOI":"10.1007\/s10637-013-0022-0","article-title":"Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients","volume":"31","author":"Lee","year":"2013","journal-title":"Invest. New Drugs"},{"issue":"5","key":"10.1016\/j.critrevonc.2020.103127_bib0640","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2016.01.012","article-title":"Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial","volume":"64","author":"Lencioni","year":"2016","journal-title":"J. Hepatol."},{"issue":"1475","key":"10.1016\/j.critrevonc.2020.103127_bib0645","article-title":"Lenvatinib (Lenvima) for thyroid cancer","volume":"57","author":"Lenvatinib","year":"2015","journal-title":"Med. Lett. Drugs Ther."},{"issue":"6","key":"10.1016\/j.critrevonc.2020.103127_bib0650","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1470-2045(15)70156-7","article-title":"Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"16","author":"Li","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2020.103127_bib0655","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2015.12.005","article-title":"A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806)","volume":"93","author":"Lim","year":"2016","journal-title":"Lung Cancer."},{"issue":"8","key":"10.1016\/j.critrevonc.2020.103127_bib0660","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.cgh.2007.04.014","article-title":"Fulminant hepatic failure secondary to erlotinib","volume":"5","author":"Liu","year":"2007","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"6","key":"10.1016\/j.critrevonc.2020.103127_bib0665","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","article-title":"EASL clinical practice guidelines: drug-induced liver injury","volume":"70","author":"Liver EAftSot","year":"2019","journal-title":"J. Hepatol."},{"issue":"11","key":"10.1016\/j.critrevonc.2020.103127_bib0670","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S1470-2045(12)70431-X","article-title":"Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial","volume":"13","author":"Long","year":"2012","journal-title":"Lancet Oncol."},{"issue":"20","key":"10.1016\/j.critrevonc.2020.103127_bib0675","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"11-12","key":"10.1016\/j.critrevonc.2020.103127_bib0680","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1111\/apt.12536","article-title":"Letter: sorafenib hepatotoxicity may be enhanced during treatment of advanced hepatocellular carcinoma in HIV-infected patients","volume":"38","author":"Mancuso","year":"2013","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.critrevonc.2020.103127_bib0685","doi-asserted-by":"crossref","DOI":"10.1007\/s10637-013-0020-2","article-title":"Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A GEMCAD study","volume":"31","author":"Martin-Richard","year":"2013","journal-title":"Invest. New Drugs"},{"issue":"2","key":"10.1016\/j.critrevonc.2020.103127_bib0690","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s10549-013-2810-9","article-title":"A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure","volume":"143","author":"Massarweh","year":"2014","journal-title":"Breast Cancer Res. Treat."},{"issue":"4","key":"10.1016\/j.critrevonc.2020.103127_bib0695","doi-asserted-by":"crossref","first-page":"387","DOI":"10.4274\/Tjh.2012.0135","article-title":"Evaluation of the safety of imatinib mesylate in 200 iraqi patients with chronic myeloid leukemia in the chronic phase: single-center study","volume":"30","author":"Matti","year":"2013","journal-title":"Turk. J. Haematol."},{"issue":"1","key":"10.1016\/j.critrevonc.2020.103127_bib0700","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.clgc.2012.09.005","article-title":"Fatal liver failure in a patient treated with sunitinib for renal cell carcinoma","volume":"11","author":"Mermershtain","year":"2013","journal-title":"Clin. Genitourin. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2020.103127_bib0705","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2013.07.022","article-title":"Phase II study of pemetrexed plus intermittent erlotinib combination therapy for pretreated advanced non-squamous non-small cell lung cancer with documentation of epidermal growth factor receptor mutation status","volume":"82","author":"Minami","year":"2013","journal-title":"Lung Cancer."},{"issue":"2","key":"10.1016\/j.critrevonc.2020.103127_bib0710","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1007\/s10620-006-9117-1","article-title":"Imatinib mesylate (gleevec) hepatotoxicity","volume":"52","author":"Mindikoglu","year":"2007","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.critrevonc.2020.103127_bib0715","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.bcp.2017.01.002","article-title":"Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: implications for hyperbilirubinemia","volume":"129","author":"Miners","year":"2017","journal-title":"Biochem. Pharmacol."},{"issue":"699","key":"10.1016\/j.critrevonc.2020.103127_bib0720","article-title":"Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program","volume":"16","author":"Moehler","year":"2016","journal-title":"BMC Cancer"},{"issue":"7","key":"10.1016\/j.critrevonc.2020.103127_bib0725","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum-pemetrexed in EGFR T790M-Positive lung Cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.critrevonc.2020.103127_bib0730","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2009.26.9571","article-title":"Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer","volume":"28","author":"Monk","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2020.103127_bib0735","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/2162-3619-3-26","article-title":"Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer: a phase I\/II randomized trial","volume":"3","author":"Moran","year":"2014","journal-title":"Exp. Hematol. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2020.103127_bib0740","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.critrevonc.2020.103127_bib0745","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1056\/NEJMc1400731","article-title":"Overall survival in renal-cell carcinoma with pazopanib versus sunitinib","volume":"370","author":"Motzer","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2020.103127_bib0750","article-title":"Bosutinib in combination with the aromatase inhibitor letrozole: a phase II trial in postmenopausal women evaluating first-line endocrine therapy in locally advanced or metastatic hormone receptor-positive\/HER2-negative breast cancer","volume":"19","author":"Moy","year":"2014","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.critrevonc.2020.103127_bib0755","doi-asserted-by":"crossref","first-page":"115","DOI":"10.14309\/crj.2014.19","article-title":"Sorafenib-induced grade four hepatotoxicity in a patient with recurrent gastrointestinal stromal tumor (GIST): a case report and review of literature","volume":"1","author":"Murad","year":"2014","journal-title":"ACG Case Rep. J."},{"issue":"593","key":"10.1016\/j.critrevonc.2020.103127_bib0760","article-title":"Treatment with gefitinib after erlotinib-induced liver injury: a case report","volume":"5","author":"Nakatomi","year":"2011","journal-title":"J. Med. Case Rep."},{"issue":"6","key":"10.1016\/j.critrevonc.2020.103127_bib0765","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1002\/ccr3.881","article-title":"Ibrutinib-induced severe liver injury","volume":"5","author":"Nandikolla","year":"2017","journal-title":"Clin. Case Rep."},{"key":"10.1016\/j.critrevonc.2020.103127_bib0770","unstructured":"NCICTCfAECv. Available at: https:\/\/evs-nci-nih-gov.gate2.inist.fr\/ftp1\/CTCAE\/About.html."},{"issue":"8","key":"10.1016\/j.critrevonc.2020.103127_bib0775","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(12)70294-2","article-title":"Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial","volume":"13","author":"Necchi","year":"2012","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2020.103127_bib0780","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1111\/cas.14384","article-title":"Safety and efficacy of first-line dacomitinib in Japanese patients with advanced non-small cell lung cancer","volume":"111","author":"Nishio","year":"2020","journal-title":"Cancer Sci."},{"issue":"11","key":"10.1016\/j.critrevonc.2020.103127_bib0785","doi-asserted-by":"crossref","DOI":"10.1001\/jama.281.11.1014","article-title":"Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic","volume":"281","author":"Nolan","year":"1999","journal-title":"Jama"},{"issue":"4","key":"10.1016\/j.critrevonc.2020.103127_bib0790","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1007\/s10120-015-0567-z","article-title":"Phase II trial of dacomitinib in patients with HER2-positive gastric cancer","volume":"19","author":"Oh","year":"2016","journal-title":"Gastric Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2020.103127_bib0795","doi-asserted-by":"crossref","DOI":"10.1038\/sj.leu.2402702","article-title":"Imatinib mesylate-induced hepato-toxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis","volume":"16","author":"Ohyashiki","year":"2002","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.critrevonc.2020.103127_bib0800","doi-asserted-by":"crossref","DOI":"10.1097\/MJT.0000000000000464","article-title":"Delayed presentation of hepatocellular liver injury after nintedanib administration","volume":"24","author":"Olin","year":"2017","journal-title":"Am. J. Ther."},{"issue":"367","key":"10.1016\/j.critrevonc.2020.103127_bib0805","article-title":"Hepatocellular toxicity associated with tyrosine kinase inhibitors: mitochondrial damage and inhibition of glycolysis","volume":"8","author":"Paech","year":"2017","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.critrevonc.2020.103127_bib0810","doi-asserted-by":"crossref","DOI":"10.1038\/tpj.2015.40","article-title":"Comprehensive genome-wide evaluation of lapatinib-induced liver injury yields a single genetic signal centered on known risk allele HLA-DRB1*07:01","volume":"16","author":"Parham","year":"2016","journal-title":"Pharmacogenomics J."},{"issue":"7","key":"10.1016\/j.critrevonc.2020.103127_bib0815","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1097\/01.meg.0000216941.42306.0e","article-title":"Imatinib mesylate-induced acute hepatitis in a patient treated for gastrointestinal stromal tumour","volume":"18","author":"Pariente","year":"2006","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"issue":"5","key":"10.1016\/j.critrevonc.2020.103127_bib0820","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S1470-2045(16)30033-X","article-title":"Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial","volume":"17","author":"Park","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2020.103127_bib0825","first-page":"7410508","article-title":"Drug-induced liver injury associated with the use of everolimus in a liver transplant patient","volume":"2018","author":"Patel","year":"2018","journal-title":"Case Rep. Transplant."},{"issue":"3","key":"10.1016\/j.critrevonc.2020.103127_bib0830","doi-asserted-by":"crossref","DOI":"10.1345\/aph.1L468","article-title":"Erlotinib-induced hepatitis complicated by fatal lactic acidosis in an elderly man with lung cancer","volume":"43","author":"Pellegrinotti","year":"2009","journal-title":"Ann. Pharmacother."},{"issue":"9","key":"10.1016\/j.critrevonc.2020.103127_bib0835","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.oraloncology.2012.03.020","article-title":"Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck","volume":"48","author":"Perez","year":"2012","journal-title":"Oral Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2020.103127_bib0840","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2009.06.012","article-title":"Nilotinib post-liver transplantation for acute hepatic failure related to imatinib","volume":"33","author":"Perini","year":"2009","journal-title":"Leuk. Res."},{"issue":"9","key":"10.1016\/j.critrevonc.2020.103127_bib0845","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s40263-016-0351-6","article-title":"Characterisation of agomelatine-induced increase in liver enzymes: frequency and risk factors determined from a pooled analysis of 7605 treated patients","volume":"30","author":"Perlemuter","year":"2016","journal-title":"CNS Drugs"},{"issue":"18","key":"10.1016\/j.critrevonc.2020.103127_bib0850","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.3748\/wjg.v17.i18.2349","article-title":"Lapatinib-induced hepatitis: a case report","volume":"17","author":"Peroukides","year":"2011","journal-title":"World J. Gastroenterol."},{"issue":"6","key":"10.1016\/j.critrevonc.2020.103127_bib0855","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S1470-2045(15)70136-1","article-title":"Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study","volume":"16","author":"Phan","year":"2015","journal-title":"Lancet Oncol."},{"issue":"27","key":"10.1016\/j.critrevonc.2020.103127_bib0860","doi-asserted-by":"crossref","first-page":"6657","DOI":"10.1200\/JCO.2005.14.696","article-title":"Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer","volume":"23","author":"Philip","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2020.103127_bib0865","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(15)70115-4","article-title":"Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial","volume":"16","author":"Pignata","year":"2015","journal-title":"Lancet Oncol."},{"issue":"1424","key":"10.1016\/j.critrevonc.2020.103127_bib0870","first-page":"71","article-title":"Ponatinib (Iclusig) for CML and Ph+ ALL","volume":"55","author":"Ponatinib","year":"2013","journal-title":"Med. Lett. Drugs Ther."},{"issue":"2","key":"10.1016\/j.critrevonc.2020.103127_bib0875","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1093\/toxsci\/KFS197","article-title":"Prediction of liver injury induced by chemicals in human with a multiparametric assay on isolated mouse liver mitochondria","volume":"129","author":"Porceddu","year":"2012","journal-title":"Toxicol. Sci."},{"issue":"16","key":"10.1016\/j.critrevonc.2020.103127_bib0880","article-title":"Unexpected side effect in mCRC: a care-compliant case report of regorafenib-induced hyperammonemic encephalopathy","volume":"96","author":"Quirino","year":"2017","journal-title":"Bull. Sch. Med. Md"},{"key":"10.1016\/j.critrevonc.2020.103127_bib0885","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1186\/s13104-015-1502-4","article-title":"Acute liver failure and seizures as a consequence of regorafenib exposure in advanced rectal cancer","volume":"8","author":"Raissouni","year":"2015","journal-title":"BMC Res. Notes"},{"issue":"1","key":"10.1016\/j.critrevonc.2020.103127_bib0890","first-page":"39","article-title":"Acute drug induced hepatitis due to erlotinib","volume":"8","author":"Ramanarayanan","year":"2007","journal-title":"JOP"},{"issue":"1","key":"10.1016\/j.critrevonc.2020.103127_bib0895","doi-asserted-by":"crossref","DOI":"10.3109\/0284186X.2013.794957","article-title":"Pazopanib after sunitinib failure in patients with metastatic renal cell carcinoma","volume":"53","author":"Rautiola","year":"2014","journal-title":"Acta Oncol. (Madr)"},{"issue":"12","key":"10.1016\/j.critrevonc.2020.103127_bib0900","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2009-12-261586","article-title":"First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia","volume":"116","author":"Ravandi","year":"2010","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.critrevonc.2020.103127_bib0905","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.1002\/cncr.29480","article-title":"Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancer","volume":"121","author":"Reckamp","year":"2015","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.critrevonc.2020.103127_bib0910","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.ejca.2014.04.008","article-title":"A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer","volume":"50","author":"Renouf","year":"2014","journal-title":"Eur. J. Cancer"},{"issue":"14","key":"10.1016\/j.critrevonc.2020.103127_bib0915","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMc1302338","article-title":"Hepatotoxicity with combination of vemurafenib and ipilimumab","volume":"368","author":"Ribas","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.critrevonc.2020.103127_bib0920","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1103690","article-title":"Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis","volume":"365","author":"Richeldi","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.critrevonc.2020.103127_bib0925","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"48","key":"10.1016\/j.critrevonc.2020.103127_bib0930","doi-asserted-by":"crossref","DOI":"10.3748\/wjg.v13.i48.6608","article-title":"Imatinib-induced fatal acute liver failure","volume":"13","author":"Ridruejo","year":"2007","journal-title":"World J. Gastroenterol."},{"issue":"12","key":"10.1016\/j.critrevonc.2020.103127_bib0935","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S1470-2045(13)70464-9","article-title":"Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial","volume":"14","author":"Rini","year":"2013","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2020.103127_bib0940","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.juro.2015.03.096","article-title":"A phase II study of pazopanib in patients with localized renal cell carcinoma to optimize preservation of renal parenchyma","volume":"194","author":"Rini","year":"2015","journal-title":"J. Urol."},{"issue":"1","key":"10.1016\/j.critrevonc.2020.103127_bib0945","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2012.10.003","article-title":"Crizotinib-induced acute hepatitis: first case with relapse after reintroduction with reduced dose","volume":"37","author":"Ripault","year":"2013","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"issue":"10 Pt 1","key":"10.1016\/j.critrevonc.2020.103127_bib0950","article-title":"[Imatinib mesylate-induced acute cytolytic hepatitis]","volume":"28","author":"Rocca","year":"2004","journal-title":"Gastroenterol. Clin. Biol."},{"issue":"16","key":"10.1016\/j.critrevonc.2020.103127_bib0955","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(15)00362-9","article-title":"Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial","volume":"16","author":"Rollig","year":"2015","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2020.103127_bib0960","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2020.103127_bib0965","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3747\/co.21.1740","article-title":"Managing treatment-related adverse events associated with Alk inhibitors","volume":"21","author":"Rothenstein","year":"2014","journal-title":"Curr. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2020.103127_bib0970","doi-asserted-by":"crossref","DOI":"10.1111\/liv.13217","article-title":"Regorafenib induced severe toxic hepatitis: characterization and discussion","volume":"36","author":"Sacre","year":"2016","journal-title":"Liver Int."},{"issue":"3","key":"10.1016\/j.critrevonc.2020.103127_bib0975","first-page":"191","article-title":"Erlotinib-induced acute hepatitis in a patient with pancreatic cancer","volume":"6","author":"Saif","year":"2008","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103127_bib0980","first-page":"423A","article-title":"Prevalence of hepatitis E markers in Spanish patients with suspected drug-induced liver injury [abstract]","volume":"66","author":"Sanjuan-Jimenez","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.critrevonc.2020.103127_bib0985","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.lungcan.2016.02.008","article-title":"Successful treatment with ceritinib after crizotinib induced hepatitis","volume":"95","author":"Sassier","year":"2016","journal-title":"Lung Cancer."},{"issue":"9","key":"10.1016\/j.critrevonc.2020.103127_bib0990","doi-asserted-by":"crossref","DOI":"10.1093\/jjco\/hyu086","article-title":"Fulminant hepatitis following crizotinib administration for ALK-positive non-small-cell lung carcinoma","volume":"44","author":"Sato","year":"2014","journal-title":"Jpn. J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2020.103127_bib0995","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V99.10.3530","article-title":"Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study","volume":"99","author":"Sawyers","year":"2002","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.critrevonc.2020.103127_bib1000","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1097\/JTO.0000000000000005","article-title":"An open-label, multicenter, randomized, phase II study of pazopanib in combination with pemetrexed in first-line treatment of patients with advanced-stage non-small-cell lung cancer","volume":"8","author":"Scagliotti","year":"2013","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2020.103127_bib1005","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1159\/000315366","article-title":"Acute fatal liver toxicity under erlotinib","volume":"3","author":"Schacher-Kaufmann","year":"2010","journal-title":"Case Rep. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2020.103127_bib1010","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2020.103127_bib1015","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1158\/1078-0432.CCR-15-1127","article-title":"A phase II trial of the multitargeted tyrosine kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid Cancer","volume":"22","author":"Schlumberger","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.critrevonc.2020.103127_bib1020","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdt056","article-title":"Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study","volume":"24","author":"Schultheis","year":"2013","journal-title":"Ann. Oncol."},{"issue":"27","key":"10.1016\/j.critrevonc.2020.103127_bib1025","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.2174\/138161205774414510","article-title":"Why drugs fail--a study on side effects in new chemical entities","volume":"11","author":"Schuster","year":"2005","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.critrevonc.2020.103127_bib1030","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/1471-2407-12-186","article-title":"Imatinib-induced liver cirrhosis in a patient with advanced gastrointestinal stroma tumor (GIST)","volume":"12","author":"Seidel","year":"2012","journal-title":"BMC Cancer"},{"issue":"19","key":"10.1016\/j.critrevonc.2020.103127_bib1035","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2006.05.7109","article-title":"Promising new treatment schedule for gefitinib responders after severe hepatotoxicity with daily administration","volume":"24","author":"Seki","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2020.103127_bib1040","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1093\/neuonc\/nox105","article-title":"Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification","volume":"19","author":"Sepulveda-Sanchez","year":"2017","journal-title":"Neuro Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2020.103127_bib1045","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/S1470-2045(14)70381-X","article-title":"Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study","volume":"15","author":"Seto","year":"2014","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2020.103127_bib1050","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s40264-013-0048-4","article-title":"Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives","volume":"36","author":"Shah","year":"2013","journal-title":"Drug Saf."},{"issue":"1","key":"10.1016\/j.critrevonc.2020.103127_bib1055","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2217\/14622416.9.1.105","article-title":"ABC multidrug transporters: structure, function and role in chemoresistance","volume":"9","author":"Sharom","year":"2008","journal-title":"Pharmacogenomics."},{"issue":"25","key":"10.1016\/j.critrevonc.2020.103127_bib1060","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.critrevonc.2020.103127_bib1065","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1311107","article-title":"Ceritinib in ALK-rearranged non-small-cell lung cancer","volume":"370","author":"Shaw","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.critrevonc.2020.103127_bib1070","doi-asserted-by":"crossref","DOI":"10.1111\/1346-8138.14206","article-title":"Dabrafenib and trametinib combination therapy safely performed in a patient with metastatic melanoma after severe liver toxicity due to vemurafenib","volume":"45","author":"Shimada","year":"2018","journal-title":"J. Dermatol."},{"issue":"11","key":"10.1016\/j.critrevonc.2020.103127_bib1075","doi-asserted-by":"crossref","DOI":"10.1038\/bjc.2017.119","article-title":"The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma","volume":"116","author":"Shroff","year":"2017","journal-title":"Br. J. Cancer"},{"issue":"19","key":"10.1016\/j.critrevonc.2020.103127_bib1080","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1200\/JCO.2008.21.3223","volume":"27","author":"Sleijfer","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2020.103127_bib1085","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2014.58.3401","article-title":"Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma","volume":"33","author":"Slomovitz","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2020.103127_bib1090","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S1470-2045(15)00006-6","article-title":"Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial","volume":"16","author":"Soria","year":"2015","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2020.103127_bib1095","doi-asserted-by":"crossref","DOI":"10.1002\/hep.28692","article-title":"Vemurafenib-induced granulomatous hepatitis","volume":"65","author":"Spengler","year":"2017","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.critrevonc.2020.103127_bib1100","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2010.31.3197","article-title":"HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer","volume":"29","author":"Spraggs","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2020.103127_bib1105","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1007\/s10637-014-0106-5","article-title":"A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients","volume":"32","author":"Spreafico","year":"2014","journal-title":"Invest. New Drugs"},{"issue":"5","key":"10.1016\/j.critrevonc.2020.103127_bib1110","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1002\/cam4.276","article-title":"A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434","volume":"3","author":"Srkalovic","year":"2014","journal-title":"Cancer Med."},{"issue":"6","key":"10.1016\/j.critrevonc.2020.103127_bib1115","doi-asserted-by":"crossref","first-page":"e368","DOI":"10.1097\/MPH.0000000000000337","article-title":"Imatinib-induced severe hepatitis in a 9-Year-old girl with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"37","author":"Suzuki","year":"2015","journal-title":"J. Pediatr. Hematol. Oncol."},{"issue":"17","key":"10.1016\/j.critrevonc.2020.103127_bib1120","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2009.26.5496","article-title":"Successful treatment with erlotinib after gefitinib-related severe hepatotoxicity","volume":"28","author":"Takeda","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2020.103127_bib1125","doi-asserted-by":"crossref","DOI":"10.1016\/j.cllc.2013.03.003","article-title":"Polymorphisms of CYP2D6 gene and gefitinib-induced hepatotoxicity","volume":"14","author":"Takimoto","year":"2013","journal-title":"Clin. Lung Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2020.103127_bib1130","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1182\/blood.V99.6.1928","article-title":"Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study","volume":"99","author":"Talpaz","year":"2002","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2020.103127_bib1135","doi-asserted-by":"crossref","DOI":"10.1007\/s10549-014-3221-2","article-title":"Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced breast cancer: NSABP Foundation FB-6, a phase II study","volume":"149","author":"Tan","year":"2015","journal-title":"Breast Cancer Res. Treat."},{"issue":"5","key":"10.1016\/j.critrevonc.2020.103127_bib1140","doi-asserted-by":"crossref","DOI":"10.1007\/s00280-008-0814-7","article-title":"Acute hepatic failure following monotherapy with sunitinib for ovarian cancer","volume":"63","author":"Taran","year":"2009","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"8","key":"10.1016\/j.critrevonc.2020.103127_bib1145","doi-asserted-by":"crossref","DOI":"10.1634\/theoncologist.2010-0081","article-title":"A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium","volume":"15","author":"Taylor","year":"2010","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.critrevonc.2020.103127_bib1150","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s11060-014-1667-z","article-title":"Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma","volume":"121","author":"Taylor","year":"2015","journal-title":"J. Neurooncol."},{"issue":"17","key":"10.1016\/j.critrevonc.2020.103127_bib1155","doi-asserted-by":"crossref","DOI":"10.1001\/jama.287.17.2273","article-title":"Safety of newly approved drugs: implications for prescribing","volume":"287","author":"Temple","year":"2002","journal-title":"Jama"},{"issue":"2","key":"10.1016\/j.critrevonc.2020.103127_bib1160","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1517\/17425255.2015.983075","article-title":"Formation of reactive metabolites and management of tyrosine kinase inhibitor-induced hepatotoxicity: a literature review","volume":"11","author":"Teo","year":"2015","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"11","key":"10.1016\/j.critrevonc.2020.103127_bib1165","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1681\/ASN.2016111232","article-title":"Bosutinib versus placebo for autosomal dominant polycystic kidney disease","volume":"28","author":"Tesar","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"issue":"3","key":"10.1016\/j.critrevonc.2020.103127_bib1170","first-page":"e86","article-title":"Imatinib mesylate-related fatal acute hepatic failure in a patient with chronic myeloid leukaemia and chronic hepatitis B infection","volume":"49","author":"Thia","year":"2008","journal-title":"Singapore Med. J."},{"issue":"2","key":"10.1016\/j.critrevonc.2020.103127_bib1175","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1470-2045(14)71181-7","article-title":"Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial","volume":"16","author":"Thomas","year":"2015","journal-title":"Lancet Oncol."},{"issue":"1-2","key":"10.1016\/j.critrevonc.2020.103127_bib1180","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2152\/jmi.63.149","article-title":"Safe and successful treatment with afatinib in three postoperative non-small cell lung cancer patients with recurrences following gefitinib\/erlotinib-induced hepatotoxicity","volume":"63","author":"Toba","year":"2016","journal-title":"J. Med. Invest."},{"issue":"17","key":"10.1016\/j.critrevonc.2020.103127_bib1185","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1016\/j.ejca.2011.07.014","article-title":"Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma","volume":"47","author":"Tomita","year":"2011","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2020.103127_bib1190","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1007\/s12032-009-9284-y","article-title":"Imatinib mesylate-induced acute liver failure in a patient with gastrointestinal stromal tumors","volume":"27","author":"Tonyali","year":"2010","journal-title":"Med. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2020.103127_bib1195","doi-asserted-by":"crossref","DOI":"10.1007\/s10637-016-0384-1","article-title":"Successful treatment with afatinib after gefitinib- and erlotinib-induced hepatotoxicity","volume":"34","author":"Ueda","year":"2016","journal-title":"Invest. New Drugs"},{"issue":"1","key":"10.1016\/j.critrevonc.2020.103127_bib1200","first-page":"e49","article-title":"Clinical features of regorafenib-induced liver injury in japanese patients from postmarketing experience","volume":"17","author":"Uetake","year":"2018","journal-title":"Clin. Colorectal Cancer"},{"issue":"9829","key":"10.1016\/j.critrevonc.2020.103127_bib1205","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"379","author":"van der Graaf","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2020.103127_bib1210","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2015.12.010","article-title":"Crizotinib-induced fatal fulminant liver failure","volume":"93","author":"van Geel","year":"2016","journal-title":"Lung Cancer."},{"issue":"7","key":"10.1016\/j.critrevonc.2020.103127_bib1215","doi-asserted-by":"crossref","DOI":"10.3109\/0284186X.2015.1004368","article-title":"Promising management of pazopanib-induced liver toxicity","volume":"54","author":"Vlenterie","year":"2015","journal-title":"Acta Oncol. (Madr)"},{"issue":"4","key":"10.1016\/j.critrevonc.2020.103127_bib1220","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1176\/appi.ajp.2013.13050709","article-title":"Antidepressant-induced liver injury: a review for clinicians","volume":"171","author":"Voican","year":"2014","journal-title":"Am. J. Psychiatry"},{"issue":"12","key":"10.1016\/j.critrevonc.2020.103127_bib1225","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1093\/annonc\/mdw414","article-title":"Hepatitis B virus reactivation in patients with solid tumors receiving systemic anticancer treatment","volume":"27","author":"Voican","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103127_bib1230","unstructured":"Votrient (pazopanib) tablets prescribing information GlaxoSmithKline. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/022465lbl.pdf."},{"issue":"3","key":"10.1016\/j.critrevonc.2020.103127_bib1235","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.25334","article-title":"Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: a report from the Children\u2019s Oncology Group","volume":"62","author":"Wagner","year":"2015","journal-title":"Pediatr. Blood Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2020.103127_bib1240","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0024-3205(94)00953-8","article-title":"Expression of the peroxisome proliferator-activated receptor gene is decreased in experimental alcoholic liver disease","volume":"56","author":"Wan","year":"1995","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.critrevonc.2020.103127_bib1245","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/pcan.2011.49","article-title":"A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago phase II Consortium\/Department of defense prostate Cancer Clinical trials consortium study","volume":"15","author":"Ward","year":"2012","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"13","key":"10.1016\/j.critrevonc.2020.103127_bib1250","doi-asserted-by":"crossref","DOI":"10.1001\/jama.1994.03510370044030","article-title":"Hepatotoxic effects of tacrine administration in patients with Alzheimer\u2019s disease","volume":"271","author":"Watkins","year":"1994","journal-title":"Jama"},{"issue":"Suppl 1","key":"10.1016\/j.critrevonc.2020.103127_bib1255","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1007\/s40264-014-0181-8","article-title":"The clinical liver safety assessment best practices workshop: rationale, goals, accomplishments and the future","volume":"37","author":"Watkins","year":"2014","journal-title":"Drug Saf."},{"issue":"4","key":"10.1016\/j.critrevonc.2020.103127_bib1260","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1345\/aph.1L528","article-title":"Fatal liver failure in a patient on acetaminophen treated with sunitinib malate and levothyroxine","volume":"43","author":"Weise","year":"2009","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.critrevonc.2020.103127_bib1265","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.tox.2014.11.002","article-title":"Regorafenib impairs mitochondrial functions, activates AMP-activated protein kinase, induces autophagy, and causes rat hepatocyte necrosis","volume":"327","author":"Weng","year":"2015","journal-title":"Toxicology"},{"issue":"6","key":"10.1016\/j.critrevonc.2020.103127_bib1270","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1530\/ERC-15-0252","article-title":"Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer","volume":"22","author":"Worden","year":"2015","journal-title":"Endocr. Relat. Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2020.103127_bib1275","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mds529","article-title":"Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803)","volume":"24","author":"Wu","year":"2013","journal-title":"Ann. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2020.103127_bib1280","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","article-title":"Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial","volume":"18","author":"Wu","year":"2017","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2020.103127_bib1285","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.ejca.2015.01.005","article-title":"Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer consortium Trial","volume":"51","author":"Xie","year":"2015","journal-title":"Eur. J. Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2020.103127_bib1290","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-15-2044","article-title":"HLA-B*57:01 confers susceptibility to pazopanib-associated liver injury in patients with Cancer","volume":"22","author":"Xu","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2020.103127_bib1295","doi-asserted-by":"crossref","first-page":"354657","DOI":"10.1155\/2012\/354657","article-title":"Treatment of non-small-Cell lung Cancer with erlotinib following gefitinib-induced hepatotoxicity: review of 8 clinical cases","volume":"2012","author":"Yano","year":"2012","journal-title":"Lung Cancer Int."},{"key":"10.1016\/j.critrevonc.2020.103127_bib1300","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejca.2019.05.032","article-title":"Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non-small-cell lung cancer patients","volume":"117","author":"Yao","year":"2019","journal-title":"Eur. J. Cancer"},{"issue":"9","key":"10.1016\/j.critrevonc.2020.103127_bib1305","article-title":"Erlotinib is a well-tolerated alternate treatment for non-small cell lung cancer in cases of gefitinib-induced hepatotoxicity","volume":"34","author":"Yonesaka","year":"2014","journal-title":"Anticancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2020.103127_bib1310","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s00280-016-3215-3","article-title":"Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor","volume":"79","author":"Yoo","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"5","key":"10.1016\/j.critrevonc.2020.103127_bib1315","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2017.01.026","article-title":"Successful osimertinib rechallenge after severe osimertinib-induced hepatotoxicity","volume":"12","author":"Yoshida","year":"2017","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2020.103127_bib1320","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.lungcan.2015.06.002","article-title":"Phase II study of a combination regimen of gefitinib and pemetrexed as first-line treatment in patients with advanced non-small cell lung cancer harboring a sensitive EGFR mutation","volume":"90","author":"Yoshimura","year":"2015","journal-title":"Lung Cancer."},{"issue":"3","key":"10.1016\/j.critrevonc.2020.103127_bib1325","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1007\/s10637-014-0154-x","article-title":"Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations","volume":"33","author":"Yoshino","year":"2015","journal-title":"Invest. New Drugs"},{"issue":"10","key":"10.1016\/j.critrevonc.2020.103127_bib1330","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1093\/annonc\/mdv288","volume":"26","author":"Yoshioka","year":"2015","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2020.103127_bib1335","first-page":"74","article-title":"Toxicity and early outcomes of regorafenib in multiply pre-treated metastatic colorectal adenocarcinoma-experience from a tertiary cancer centre in India","volume":"4","author":"Zanwar","year":"2016","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.critrevonc.2020.103127_bib1340","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2016.05.002","article-title":"Successful treatment with afatinib after grade 3 hepatotoxicity induced by both gefitinib and erlotinib in EGFR mutation-positive non-small cell lung cancer","volume":"99","author":"Zenke","year":"2016","journal-title":"Lung Cancer."},{"issue":"8","key":"10.1016\/j.critrevonc.2020.103127_bib1345","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1007\/s00204-016-1918-1","article-title":"Effects of 31 FDA approved small-molecule kinase inhibitors on isolated rat liver mitochondria","volume":"91","author":"Zhang","year":"2017","journal-title":"Arch. Toxicol."},{"issue":"1","key":"10.1016\/j.critrevonc.2020.103127_bib1350","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1016\/j.cllc.2018.09.006","article-title":"Severe acute hepatitis in a patient receiving alectinib for ALK-Positive non-small-Cell lung Cancer: histologic analysis","volume":"20","author":"Zhu","year":"2019","journal-title":"Clin. Lung Cancer"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842820302638?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842820302638?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:34:34Z","timestamp":1760902474000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842820302638"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":270,"alternative-id":["S1040842820302638"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2020.103127","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multikinase inhibitor-induced liver injury in patients with cancer: A review for clinicians","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2020.103127","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103127"}}